6471 RESULTS
Sort By:
A cast of blood biomarkers for Alzheimer's has emerged from studies in research cohorts, and is now being put to the test in community cohorts. At AAIC, direct comparisons of top contenders showed that some detect amyloid and impending cognitive decline.
In a small pilot study, tailoring lifestyle changes to the individual boosted cognition, with an effect size three times that seen in the Finger trial.
The more foliage near a person’s residence, the less likely they are to have either disease.
A protein that repairs synapses after hibernation falters in some models of neurodegenerative diseases.
Dare We Say Consensus Achieved: Lecanemab Slows the Disease Brexpiprazole Eases Agitation in People with AD; So Does Being in a Trial Two New Stabs at Vaccinating People Against Pathologic Tau Cognitive Tests Taken at Home Are on Par with In-Clinic Assess
Plasma p-tau climbs as bears sleep. Post-torpor, tau reverts to normal. Does neuronal metabolic activity have to do with it?
In a 45-page report, two House committees rebuked the agency for working too closely with drug sponsor Biogen.
Eisai’s anti-amyloid antibody got the nod via the accelerated approval pathway; the company is expected to apply for traditional approval within days.
A collection of antibodies against microglial proteins is starting off a new database on Alzforum.
Recent reports of three deaths in the lecanemab extension study suggest that blood thinners, lecanemab, and cerebral amyloid angiopathy could be a dangerous combination.
Last year saw major advances in multi-omics analyses using human tissues, better animal models, deeper functional studies of gene variants, dissections of neuroimmune cell biology, and more.
Researchers explored how the brain’s immune cells influence disease, and how cells and signals from outside the brain pitch in.
By triggering release of mitochondrial DNA, tau fibrils may set off a cytosolic sensor that activates the interferon response. Blocking this sensor spared neurons and memory in mice.
The actin-binding protein associated with tau aggregates in people with PSP, and rare variants in the gene associated with the disease.
Therapeutics research in the field ended on high hopes that lecanemab’s Phase 3 data would carry this anti-Aβ antibody to regulatory approval in country after country in 2023. This wave drew power from progress in biomarker research; but alas, much work remains to be done.
